Pediatric blood & cancer
-
Pediatric blood & cancer · Jan 2011
Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
More evidence of the safety and effectiveness of hydroxyurea (HU) in community-based cohorts of pediatric patients with sickle cell disease (SCD) are needed. The association of HU with organ-specific clinical complications and adverse events is examined herein. ⋯ Extending previous findings to routine practice settings, HU is being administered to the most severely ill children with SCD, many of whom had already started to develop organ-specific complications, but it is not associated with development of serious adverse events.